ArticleJournal of human immunity2025
Prevalence and association of type I IFN autoantibodies with clinical outcomes in critically ill Brazilian COVID-19 patients.
Article in Journal of human immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C.Journal of human immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Anti-type I interferon (IFN) autoantibodies (auto-Abs) impair antiviral immunity and have been associated with critical COVID-19. However, their prevalence and impact in Latin American populations remain incompletely delineated. This study assessed the prevalence of auto-Abs neutralizing 10 ng/mL IFN-α2 and IFN-ω in critically ill COVID-19 patients from a Brazilian cohort and their association with clinical outcomes. Among 209 patients, 14 (6.7%) tested positive, including 9.4% of deceased individuals. The proportion was 13.2% in patients older than 65 years. These individuals exhibited increased MIP-1β levels, altered hematological parameters, and low IFN-α levels. Survival analysis indicated shorter hospitalization survival times in auto-Ab-positive patients (log-rank = 0.01). The prevalence aligns with global reports, predominantly affecting older individuals. Our findings highlight the association between type I IFN auto-Abs and worse clinical outcomes, emphasizing the need for further studies to understand their biological role and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.